Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Presenting at Cowen Healthcare Conference

8 Mar 2018 07:00

RNS Number : 0452H
Realm Therapeutics PLC
08 March 2018
 

Realm Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

 

MALVERN, PA, March 8 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that Alex Martin, CEO, will be presenting at the Cowen and Company 38th Annual Health Care Conference, on Tuesday, March 13, 2018 at 10:00 a.m. ET at the Boston Marriott Copley Place. 

 

A live and archived webcast of the Cowen presentation will be available on the Events and Presentations page of the Company's website. An updated copy of Realm's corporate presentation will be available on March 13 on the Company's website at www.realmtx.com

 

About Realm Therapeutics

 

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the intersection between innate and adaptive immunity, to influence immune signaling and to change the course of immune-mediated diseases in adults and children. Realm's lead drug development programs utilize the Company's proprietary immunomodulatory technology for the treatment of Allergic Conjunctivitis (PR013) and Atopic Dermatitis (PR022) and Realm is exploring its efficacy in Acne and additional Dermatology and Ophthalmology indications as well as other disease areas. For more information on Realm Therapeutics, Inc. please visit www.realmtx.com.

 

Forward Looking Statements

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

Contact:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US: +44 (0) 20 3727 1000

US: +1 212 600 1902

 

Argot Partners

Stephanie Marks

+1 212 600 1902

 

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

 

N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAPDXELAPEFF
Date   Source Headline
5th Sep 20114:35 pmRNSPrice Monitoring Extension
23rd Aug 20117:00 amRNSHalf Yearly Report
21st Jul 20117:00 amRNSRe Settlement with Misonix
15th Jun 201110:06 amRNSResult of AGM
18th May 20117:00 amRNSAnnual Information Update
17th May 20114:58 pmRNSUK Division Update
6th May 20117:00 amRNSAnnual Report and Accounts Available
28th Apr 20116:21 pmRNSFinal Results
28th Apr 20116:21 pmRNSInterim Management Statement
4th Apr 20112:29 pmRNSHolding(s) in Company
31st Mar 20114:53 pmRNSHolding(s) in Company
31st Mar 20114:52 pmRNSHolding(s) in Company
31st Mar 20114:51 pmRNSHolding(s) in Company
31st Mar 20117:00 amRNSTotal Voting Rights
22nd Mar 20117:00 amRNSPlacing of New Ordinary Shares
15th Mar 20114:24 pmRNSPotential Sale of Endoscopy Division
4th Feb 201111:51 amRNSBlocklisting Interim Review
2nd Feb 20111:18 pmRNSPre-Close Trading Update
9th Dec 20108:58 amRNSBlocklisting Interim Review
30th Nov 20107:00 amRNSChange of Adviser
8th Nov 20107:00 amRNSInterim Management Statement
29th Oct 20109:56 amRNSResult of General Meeting
11th Oct 20104:00 pmRNSProposed New Long Term Incentive Plan
2nd Sep 20102:44 pmRNSDirector/PDMR Shareholding
31st Aug 20107:00 amRNSHalf Yearly Report
9th Aug 20107:00 amRNSTrading Statement
22nd Jul 20101:36 pmRNSHolding(s) in Company
22nd Jul 20101:30 pmRNSHolding(s) in Company
30th Jun 20109:47 amRNSResult of AGM
21st Jun 20101:10 pmRNSReplacement: Director/PDMR Shareholding
21st Jun 20107:00 amRNSDirector/PDMR Shareholding
16th Jun 20107:00 amRNSBoard Change
14th Jun 20101:38 pmRNS2010 General Meeting Results
14th Jun 20109:16 amRNSAnnual Information Update
28th May 20102:55 pmRNSPublication of Circular
28th May 20107:32 amRNSResumption of Trading
28th May 20107:30 amRNSRestoration
28th May 20107:02 amRNSInterim Management Statement
28th May 20107:01 amRNSFinal Results
28th May 20107:00 amRNSIssue of Secured Convertible Loan Notes
24th May 20102:55 pmRNSHolding(s) in Company
30th Apr 20107:54 amRNSTemporary Suspension
30th Apr 20107:30 amRNSTemporary Suspension - PuriCore Plc
23rd Apr 20107:00 amRNSPuriCore Raises $1.8 Million
24th Feb 20107:00 amRNSBlocklisting Interim Review
20th Jan 20107:00 amRNSTrading Statement
4th Dec 20097:00 amRNSWins Emerging Life Sciences Company of the Year
12th Nov 20097:00 amRNSChange of Adviser
11th Nov 20092:00 pmRNSClinical Results for Vashe Wound Therapy
3rd Nov 20097:00 amRNSInterim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.